COMMUNIQUÉS West-GlobeNewswire

-
Enzymotec Shareholders Approve Proposed Acquisition by Frutarom
11/12/2017 - 23:15 -
Scythian Biosciences Corp. Announces Appointment of Ottis Anderson to Pro Athlete Advisory Committee
11/12/2017 - 23:07 -
Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study
11/12/2017 - 22:46 -
Karmanos Cancer Institute’s 24th Annual Partners Night continues to drive the future of cancer research
11/12/2017 - 22:34 -
Mustang Bio's MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase 1 Clinical Trial
11/12/2017 - 22:30 -
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
11/12/2017 - 22:30 -
Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting
11/12/2017 - 22:30 -
Minerva Neurosciences Names Richard Russell President
11/12/2017 - 22:30 -
Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis
11/12/2017 - 22:21 -
AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017
11/12/2017 - 22:20 -
Avinger Announces Change in Board Leadership
11/12/2017 - 22:15 -
Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M
11/12/2017 - 22:15 -
Wright Medical Group N.V. to Present at 36th Annual J.P. Morgan Healthcare Conference
11/12/2017 - 22:15 -
argenx announces launch of proposed public offering in the United States
11/12/2017 - 22:11 -
Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation
11/12/2017 - 22:05 -
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments
11/12/2017 - 22:05 -
Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer
11/12/2017 - 22:05 -
OrthoPediatrics Corp. Launches New Wrist Fusion Plate System
11/12/2017 - 22:05 -
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting
11/12/2017 - 22:04
Pages